Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-Surgical Letrozole in Operable Hormone-Sensitive Breast Cancer
NCT03747042Phase 2Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Nov 2018
- Primary completion
- Feb 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of letrozole in breast cancer, sponsored by UT Southwestern Medical Center. Primary endpoint: Ki67 Index in Highly Hormone-dependent Breast Cancers vs. Those That Are Not. Started Nov 2018; status: completed.
02
Drugs
letrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03747042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03747042.